摘要
目的分析阿司匹林在生殖医学中心门诊用药情况。方法抽取2017年1月—2017年12月本院生殖医学中心门诊阿司匹林处方,对患者基本信息、临床诊断、用药情况进行统计分析。根据药品说明书内容,判断是否超说明书用药,并参考妇产科临床相关诊疗指南、专家共识及相关文献等,对该药品在生殖医学领域的临床使用情况进行评价。结果共抽取阿司匹林处方2 569张,其中25 mg阿司匹林处方2 530张(98.48%), 100 mg阿司匹林处方39张(1.52%)。阿司匹林用量均≤150 mg·d-1,用法用量多为50 mg每日2次(47.60%)及25 mg每日2次(45.62%)。阿司匹林多为单一用药(2 043频次,79.53%)。联合用药526频次(20.47%),其中使用最普遍的药物为泼尼松片(44.1%)和地屈孕酮片(16.6%)。阿司匹林均为超适应证用药,多用于女性不育症(2 432频次, 94.67%)、确认妊娠(96频次,3.74%)及多囊卵巢综合征(28频次, 1.09%)。结论本院生殖医学中心门诊阿司匹林用药多为低规格、低剂量、单一用药,虽都为超说明书用药,但大多数有文献依据支持,阿司匹林在生殖医学领域的应用仍需引起重视。
AIM To analysis the application of aspirin in the clinic of reproductive medical center.METHODS The outpatient prescriptions of aspirin in the clinic of reproductive medical center of our hospital from January to December in 2017 were randomly selected. The basic information, clinical diagnosis and medications of patients were statistically analyzed. Whether the drug was off-label use was determined by the drug label. The clinical applications in reproductive medicine were evaluated according to the relevant guidelines, expert consensus and literatures. RESULTS A total of 2 569 of aspirin prescriptions were selected.There were 2 530 prescriptions of aspirin 25 mg(98.48%) and 39 prescriptions of aspirin 100 mg(1.52%).The dosage of aspirin was less than 150 mg·d-1. Most of the dosages were 50 mg twice a day( 47.60%) and25 mg twice a day(45.62%). Most aspirins were single used(2 043, 79.53%). There were 526 prescriptions( 20.47%) of combined drugs. The most common combination drugs were prednisone tablets( 44.1%) and dydrogesterone tablets(16.6%). All of the use of aspirin was off-label. The common indications of aspirin were female infertility(n = 2 432, 94.67%), pregnancy(n = 96, 3.74%) and polycystic ovary syndrome(n = 28,1.09%). CONCLUSION The common use of aspirin in the clinic of reproductive medical center of our hospital is low specification, low dose and single dose. Most of the off-label uses are evidence-based. More attention should be paid to the application of aspirin in the reproductive medicine.
作者
刘洪奕
胡丽秀
LIU Hong-yi;HU Li-xiu(Department of Pharmacy,Ruijin Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,SHANGHAI 200025,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2018年第11期655-658,共4页
Chinese Journal of New Drugs and Clinical Remedies